首页|阿兹夫定片治疗新型冠状病毒肺炎引起药物性肝损伤真实世界研究

阿兹夫定片治疗新型冠状病毒肺炎引起药物性肝损伤真实世界研究

扫码查看
目的:探究真实世界阿兹夫定片治疗新型冠状病毒肺炎(COVID-19)引起药物性肝损伤(drug-induced liver injury,DILI)发生情况和危险因素,为临床安全用药提供参考。方法:回顾性收集2022年11月30日至2023年1月26日于合肥市第二人民医院住院期间服用阿兹夫定片治疗COVID-19患者病历,记录每位患者年龄、性别、体质量、用药剂量、治疗疗程、合并用药情况、肝功能指标、药物肝损不良反应等信息,统计阿兹夫定发生DILI的基本特征;并将患者分为未发生DILI组和发生DILI组,比较两组患者基本特征和药物治疗的差异,进一步探讨阿兹夫定引起DILI的影响因素。结果:共纳入符合条件的患者294例,发生DILI为17例,占比5。78%;DILI临床分型方面,肝细胞损伤型4例,胆汁淤积型6例,混合型7例;DILI因果关系评估方面,17例DILI中极可能1例,很可能12例,可能4例;DILI严重程度分级方面,17例患者中轻度肝损伤(1级)10例,中度肝损伤(2级)5例,2例患者由于检测数据不全而未分级;DILI发生时间方面,17例患者阿兹夫定平均用药疗程为(7。6±3。7)d,DILI发生时间为服药后的(6。4±3。9)d。影响因素方面,合并用药数量、低蛋白血症、危重患者是发生DILI的显著影响因素(P<0。05)。结论:阿兹夫定治疗COVID-19引起的DILI为临床常见不良反应,严重程度方面多为轻、中度不良反应,临床使用总体安全性和耐受性良好;临床使用前应评估患者病理状态,对于合并低蛋白血症和/或危重患者,应进行全面评估后谨慎用药;使用过程中应尽量减少合并用药数量,特别是避免与其有相互作用的药物联合使用,以此避免DILI的发生。
A real-world study of azivudine tablets for drug-induced liver injury caused by novel coronavirus pneumonia
OBJECTIVE To explore the occurrences and risk factors of drug-induced liver injury(DILI)caused by azivudine tablets for corona virus disease 2019(COVID-19)in real world and provide references for safe clinical dosing.METHODS From November 30,2022 to January 26,2023,medical records were retrospectively reviewed for 294 hospitalized patients taking azivudine tablets for COVID-19.Age,gender,weight,dosage,course of treatment,co-medication,liver function parameters and adverse reactions of causing liver injuries were recorded.Basic characteristics of azvudine DILI were examined.They were assigned into two groups of non-DILI and DILI.The inter-group differences of basic characteristics and medications were com-pared and the influencing factors of azivudine-induced DILI further discussed.RESULTS Among them,17 cases(5.78%)developed DILI.In clinical classification of DILI,the types were hepatocyte injury(n=4),cholestasis(n=6)and mixed(n=7).Regarding DILI causality assessment,the likelihood was extreme(n=1),quite(n=12)and possible(n=4).As for DILI sever-ity,the grade was Ⅰ(mild,n=10),Ⅱ(moderate,n=5)and unknown(n=2).As for occurrence time of DILI,average treat-ment duration of azvudine was(7.6±3.7)days and occurrence time of DILI(6.4±3.9)days post-dosing.Number of co-medications,hypoproteinemia and critical illness were significant influencing factors for the development of DILI(P<0.05).CONCLUSION DILI induced by azivudine for COVID-19 is a common clinical adverse reaction.Most adverse reactions are mild or moderate in severity.The overall safety and tolerability of azivudine are decent in clinical practices.The pathological sta-tus of patients should be evaluated prior to clinical dosing.For individuals with hypoproteinemia and/or critically illness,azivudine should be carefully dosed after comprehensive evaluations.During dosing,the number of co-medications should be minimized,especially interacting co-medications should be avoided to avoid the occurrence of DILI.

azvudinenovel coronavirus pneumoniadrug-induced liver injury

刘秀珍、刘建军、方兴、李萌、赵晶晶、邢海燕

展开 >

合肥市第二人民医院药学部,安徽合肥23000

合肥市第二人民医院重症医学科,安徽合肥23000

阿兹夫定片 新型冠状病毒肺炎 药物性肝损伤

安徽省高等学校科研项目(自然科学类)

2022AH050712

2024

中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
年,卷(期):2024.44(9)
  • 22